On September 1, 2021, a newer formulation of paliperidone palmitate, Invega Hafyera, was approved by the US FDA which is available as an injection every six months.
In September 2021, the US FDA approved a new formulation of paliperidone palmitate called Invega Hafyera, which is now available as an injection given every six months.